Wedbush set a $35.00 price target on Lexicon Pharmaceuticals (NASDAQ:LXRX) in a report released on Tuesday morning, Stock Target Advisor reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Other research analysts also recently issued research reports about the stock. BidaskClub downgraded shares of Lexicon Pharmaceuticals from a hold rating to a sell rating in a research note on Wednesday, March 27th. ValuEngine downgraded shares of Lexicon Pharmaceuticals from a hold rating to a sell rating in a research note on Monday, May 20th. Zacks Investment Research raised shares of Lexicon Pharmaceuticals from a hold rating to a buy rating and set a $6.50 price objective for the company in a research note on Tuesday, May 28th. Gabelli raised shares of Lexicon Pharmaceuticals from a sell rating to a hold rating in a research note on Monday, March 25th. Finally, Needham & Company LLC reaffirmed a hold rating on shares of Lexicon Pharmaceuticals in a research note on Monday, March 25th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. The stock currently has an average rating of Hold and a consensus price target of $16.38.

NASDAQ LXRX opened at $5.65 on Tuesday. Lexicon Pharmaceuticals has a 12 month low of $4.25 and a 12 month high of $13.97. The stock has a market cap of $600.44 million, a PE ratio of -4.96 and a beta of 0.78.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($0.21) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.21). Lexicon Pharmaceuticals had a negative net margin of 214.93% and a negative return on equity of 911.37%. The company had revenue of $9.20 million during the quarter, compared to the consensus estimate of $13.26 million. During the same quarter in the prior year, the company posted ($0.40) EPS. The company’s quarterly revenue was down 63.8% compared to the same quarter last year. Sell-side analysts forecast that Lexicon Pharmaceuticals will post -0.47 earnings per share for the current year.

Several large investors have recently modified their holdings of the company. Clearbridge Investments LLC raised its position in shares of Lexicon Pharmaceuticals by 3.4% during the 1st quarter. Clearbridge Investments LLC now owns 1,292,130 shares of the biopharmaceutical company’s stock valued at $7,184,000 after acquiring an additional 42,540 shares in the last quarter. BlueMountain Capital Management LLC acquired a new stake in shares of Lexicon Pharmaceuticals during the 1st quarter valued at approximately $611,000. BlueCrest Capital Management Ltd acquired a new stake in shares of Lexicon Pharmaceuticals during the 1st quarter valued at approximately $71,000. M&T Bank Corp acquired a new stake in shares of Lexicon Pharmaceuticals during the 1st quarter valued at approximately $66,000. Finally, Macquarie Group Ltd. acquired a new stake in shares of Lexicon Pharmaceuticals during the 1st quarter valued at approximately $2,502,000. Institutional investors and hedge funds own 98.30% of the company’s stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Further Reading: Green Investing

Analyst Recommendations for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.